19.25

1.91% 0.36

After Hours: 19.25

Syndax Pharmaceuticals Inc (SNDX)

Overview News Price History Option Chain Financials Discussions Forecast

Syndax Pharmaceuticals Inc stock is traded at $19.25, with a volume of 1.16M. It is up +1.91% in the last 24 hours and down -6.33% over the past month. Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Previous Close:

$18.89

Open:

$18.7

24h Volume:

1.16M

Relative Volume:

1.13

Market Cap:

$1.64B

Revenue:

$139.71M

Net Income/Loss:

$-209.36M

P/E Ratio:

-7.4612

EPS:

-2.58

Net Cash Flow:

$-160.60M

1W Performance:

+7.36%

1M Performance:

-6.33%

6M Performance:

-19.12%

1Y Performance:

+32.58%

1-Day Range:

$18.70

$19.59

1-Week Range:

$17.72

$19.59

52-Week Range:

$11.21

$25.34

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name

Syndax Pharmaceuticals Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

781-419-1400

Address

35 GATEHOUSE DRIVE, WALTHAM, MA

Employee

184

Twitter

@syndax

Next Earnings Date

2024-08-01

Latest SEC Filings

SNDX's Discussions on Twitter

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Dec-22-23	Initiated	Mizuho	Buy
Oct-25-23	Initiated	BofA Securities	Buy
Oct-11-23	Initiated	Goldman	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy
Apr-17-23	Resumed	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jan-03-23	Initiated	JP Morgan	Overweight
Jul-28-22	Resumed	B. Riley Securities	Buy
Apr-11-22	Initiated	H.C. Wainwright	Buy
Feb-15-22	Initiated	Goldman	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
May-25-21	Initiated	Citigroup	Buy
Feb-18-21	Initiated	B. Riley Securities	Buy
Dec-03-20	Initiated	Stifel	Buy
May-22-20	Upgrade	Citigroup	Neutral → Buy
May-22-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-18-20	Downgrade	Citigroup	Buy → Neutral
May-11-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Reiterated	H.C. Wainwright	Buy
Mar-08-19	Reiterated	H.C. Wainwright	Buy
Jan-04-19	Initiated	Robert W. Baird	Outperform
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Mar-16-17	Initiated	FBR & Co.	Outperform
Mar-02-17	Initiated	Instinet	Buy
Oct-07-16	Initiated	Guggenheim	Buy
Mar-28-16	Initiated	Citigroup	Buy
Mar-28-16	Initiated	JMP Securities	Mkt Outperform
Mar-28-16	Initiated	Morgan Stanley	Overweight

View All

Syndax Pharmaceuticals Inc Stock (SNDX) Latest News

06:48 AM

Investing in Syndax Pharmaceuticals Inc (SNDX) Is Getting More Attractive - Knox Daily

06:48 AM

Sep 29, 2024

Public Employees Retirement Association of Colorado Has $282,000 Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Sep 29, 2024

Clearline Capital LP Makes New $866,000 Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Sep 29, 2024

Renaissance Technologies LLC Has $4.40 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Sep 29, 2024

Renaissance Technologies LLC Has $4.40 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Sep 29, 2024

Sep 27, 2024

Marshall Wace LLP Lowers Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Sep 26, 2024

Sep 25, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Ensign Peak Advisors Inc - Defense World

Sep 25, 2024

Profund Advisors LLC Has $682,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Sep 25, 2024

Sep 24, 2024

Stocks of Syndax Pharmaceuticals Inc (SNDX) are poised to climb above their peers - SETE News

Sep 24, 2024

Avoro Capital Advisors LLC Reduces Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Sep 24, 2024

Sep 23, 2024

Potential Price Increase for Syndax Pharmaceuticals Inc (SNDX) After Recent Insider Activity - Knox Daily

Sep 23, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Avoro Capital Advisors LLC - Defense World

Sep 23, 2024

Syndax Pharmaceuticals: One Down And One To Go (NASDAQ:SNDX) - Seeking Alpha

Sep 23, 2024

Sep 22, 2024

Critical Survey: Syndax Pharmaceuticals (NASDAQ:SNDX) vs. Journey Medical (NASDAQ:DERM) - Defense World

Sep 22, 2024

(SNDX) Investment Analysis and Advice - Stock Traders Daily

Sep 22, 2024

Inspire Investing LLC Grows Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Sep 22, 2024

State of New Jersey Common Pension Fund D Decreases Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Sep 22, 2024

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Sep 22, 2024

Sep 20, 2024

E Fund Management Co. Ltd. Cuts Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Sep 20, 2024

Syndax Pharmaceuticals: Navigating Through A Pivotal Year (NASDAQ:SNDX) - Seeking Alpha

Sep 20, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Holdings Boosted by Seven Eight Capital LP - Defense World

Sep 20, 2024

Seven Eight Capital LP Increases Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Sep 20, 2024

Sep 19, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Sep 19, 2024